Amgen's global Phase III DeLLphi-304 trial of Imdelltra has met its primary endpoint at a planned interim analysis for ...

In a small study, lactotransferrin (LTF) was identified as a potentially important biomarker in extensive-stage small cell ...

In the Phase III DeLLphi-304 trial, patients with small cell lung cancer administered Imdelltra achieved a statistically ...

An exploratory analysis shows a reduction in extrathoracic metastases and prolonged time to progression or death due to any ...

ST-001, an intravenous nanoformulation of fenretinide, will be evaluated in a phase 1a/1b small cell lung cancer trial.

Tarlatamab-dlle significantly improves overall survival in SCLC compared to standard chemotherapy, as demonstrated in the phase 3 DeLLphi-304 trial. The bispecific T-cell engager targets DLL3 on ...

David Spigel, MD, discusses the significant benefits of durvalumab as consolidation therapy following standard ...

Nearly a year after winning an accelerated approval for its DLL3-targeting small cell lung cancer (SCLC) therapy Imdelltra, ...

Amgen has shared positive results from a late-stage study of its immunotherapy Imdelltra (tarlatamab-dlle) in small cell lung cancer (SCLC). The global DeLLphi-304 trial has been comparing the drug ...

Molecular Partners AG’s MOLN share price has surged by 5.04%, which has investors questioning if this is right time to sell.

WASHINGTON, D.C. - The Lawyer’s Committee for Civil Rights Under Law has filed a brief here April on behalf of the Southern ...

First Global Phase 3 Trial Showing Substantial Survival Advantage Over Chemotherapy, for Patients With Progression On or After Platinum-Based Chemotherapy ...